Abstract:Abstract Introduction Key barriers restrict the utility (or use) of genetic information in making treatment decisions in metastatic PCa. First, the lack of platforms that link genomic and clinical outcome data limits our ability to uncover clinico-genomic associations. Second, predictions based on univariate biomarkers (e.g. individual mutations), are insufficient given the heterogeneity of metastatic genomes. Third, lack of predictive biomarkers for standard therapies limits the use of testing to prioritize patients for trials. We initiated CAPSTONE, a clinico-genomic resource and research study, to overcome these barriers. Methods CAPSTONE comprises three complementary discovery n=325, validation n=429, and real-world n=1,800 clinico-genomic cohorts, reflecting data characteristics in the research and real-world contexts. The discovery cohort includes PCa patients with RNA-seq and matched tumor germline exome sequencing (WES) from UM, the validation cohort has similar WES/RNA-seq data from non-UM mCRPC patients from the SU2C study. The real-world dataset is from PROMISE, a multi-institutional effort among 25+ PCa centers across the US utilizing commercial tests. Genetic and clinical data are harmonized through a uniform computational workflow and interoperable clinical data model. Results In this early report, we present results from the analysis of the discovery cohort with a median follow of 106 months (IQR, 90-121) and 91% PCa adenocarcinoma histology (n=292/325). 36 samples were from patients with localized disease, 101 from metastatic hormone sensitive PCa (mHSPC) and 191 from metastatic castrate resistant PCa (mCRPC). We called driver mutations, measured chromosomal instability (CIN), and obtained RNA-seq based readouts of pathway activity and immune infiltration. We were able to confirm all reported clinico-genomic associations in metastatic PCa, and identify multiple new ones. AR amplifications were found in 10% of mHSPC and were associated with significantly shorter survival on first-line therapy (p=0.0061). TP53 mutations were associated with worse OS from the time of biopsy on multivariable analysis (HR: 2.2; 1.7-2.9, p<0.001). OS from biopsy was worse for dual TP53/RB1 mutants when compared to TP53 or RB1 mutants alone, independent of the disease state at time of biopsy (HR, 4.3; 95% CI: 2.7-7.0, p<0.001). Surprisingly, both TP53 loss (p<0.001) and AR (p<0.001) amplification was associated with increased CIN (wGII). CIN increased in progression from localized to mHSPC to mCRPC (p=3e-5) and was independently associated with worse OS when controlled for covariates (HR: 3.28; 95% CI: 1.39-7.80, p=0.007). wGII-high tumors show upregulation of EMT-associated genes (q=6.8e-14), downregulation of AR-target genes (q=2.7e-6), and show lower CD8+ T cell levels (R=-0.24,p=7.7e-4). Conclusions We demonstrate the utility of CAPSTONE in identifying single-gene and complex genetic biomarkers associated with patient outcomes. Most notably, we identify CIN as one of the strongest independent genetic predictors of poor patient outcomes in PCa. Citation Format: Marcin Cieslik, Ryan Rebernick, Liat Hammer, Matt McFarlane, Thomas Westbrook, Yi-Mi Wu, Dan Robinson, Dan Spratt, Ajjai Alva, William Jackson, Zachery Reichert, Arul Chinnaiyan, Joshi Alumkal, Robert Dess. The carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE) project: A clinico-genomic resource to enable patient-centric genomic research and improve the actionability of genetic testing in metastatic prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr PR011.

Abstract 6436: Tumor-educated platelets for therapy stratification of metastasized castration resistant prostate cancer (CRPC)

Abstract 6563: PSMA-based detection and global proteome-based analysis of circulating tumor cells in castration resistant prostate cancer patients

Abstract 3665: Stratifying prostate cancer patients through circulating genes related to prostate cell subtypes, drug targets, and therapeutic resistance

Abstract PR005: Tracing the clonal dynamic of metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA

Abstract 3699: Identifying novel resistance biomarkers in circulating tumor cell-expressed transcriptomes of metastatic castration-resistant prostate cancer patients treated with androgen receptor signaling inhibitors

Abstract PR013: Unlocking the proteome of metastatic prostate cancer circulating tumor cells

Abstract B002: Determination of tumor PSMA expression and response to Lutetium-PSMA in men with prostate cancer using a novel epigenomic liquid biopsy platform

Abstract 1209: Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab

Abstract 3690: Monitoring prostate specific membrane antigen or androgen receptor expression on circulating stromal cells in advanced prostate cancer patients and their correlation with patient response

Abstract 5031: Identification of predictive/prognostic biomarkers in metastatic castration-resistant prostate cancer patients using plasma cell-free total RNA-sequencing

Abstract PR011: The carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE) project: A clinico-genomic resource to enable patient-centric genomic research and improve the actionability of genetic testing in metastatic prostate cancer

Abstract 104: Profiling peripheral blood to predict response to targeted androgen receptor axis therapy in mice

Abstract 70: Unlocking the potential of the T-cell receptor in prostate cancer

Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer.

Abstract 1175: Differential patterns of immune infiltration in the tumor immune microenvironment associate with therapeutic response in primary prostate cancer following chemohormonal therapy

Abstract 7351: Delineating the prostate cancer tumor microenvironment through scRNA-seq profiling at different timepoints

Abstract P6-10-27: the Clinical Utility of Mutations Detected on Circulating Tumor Cells: A Proof of Concept Study Based on a Metastasized Breast Cancer Index Patient

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Abstract 852: Predicting progression in metastatic castrate-sensitive prostate cancer by coupling PSA and testosterone dynamics to a mechanistic mathematical model

Abstract 7652: Plasma markers of hemostasis, fibrinolysis, and angiogenesis prior to androgen deprivation therapy (ADT) in progressive prostate cancer (PC) and associations with long-term thrombotic events and survival

Abstract 3409: Whole genome sequencing of liquid tumor biopsies (ctDNA) from men with metastatic castration resistant prostate cancer